IL156781A0 - (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes - Google Patents
(diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetesInfo
- Publication number
- IL156781A0 IL156781A0 IL15678102A IL15678102A IL156781A0 IL 156781 A0 IL156781 A0 IL 156781A0 IL 15678102 A IL15678102 A IL 15678102A IL 15678102 A IL15678102 A IL 15678102A IL 156781 A0 IL156781 A0 IL 156781A0
- Authority
- IL
- Israel
- Prior art keywords
- diazolo
- teatment
- pyrimidines
- pyridinyl
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0100569A SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | New compounds |
| PCT/SE2002/000271 WO2002065979A2 (en) | 2001-02-20 | 2002-02-18 | (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL156781A0 true IL156781A0 (en) | 2004-02-08 |
Family
ID=20283059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15678102A IL156781A0 (en) | 2001-02-20 | 2002-02-18 | (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7345050B2 (cs) |
| EP (1) | EP1373266A2 (cs) |
| JP (1) | JP4475869B2 (cs) |
| KR (1) | KR20030084935A (cs) |
| CN (1) | CN1294131C (cs) |
| BG (1) | BG108070A (cs) |
| BR (1) | BR0206935A (cs) |
| CA (1) | CA2434648A1 (cs) |
| CZ (1) | CZ20032235A3 (cs) |
| EE (1) | EE200300400A (cs) |
| HK (1) | HK1070071A1 (cs) |
| HU (1) | HUP0303254A2 (cs) |
| IL (1) | IL156781A0 (cs) |
| IS (1) | IS6868A (cs) |
| MX (1) | MXPA03007320A (cs) |
| NO (1) | NO20033679L (cs) |
| NZ (1) | NZ526783A (cs) |
| PL (1) | PL363393A1 (cs) |
| RU (1) | RU2003121307A (cs) |
| SE (1) | SE0100569D0 (cs) |
| SK (1) | SK10252003A3 (cs) |
| WO (1) | WO2002065979A2 (cs) |
| ZA (1) | ZA200306171B (cs) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| EP1490354A1 (en) | 2002-03-09 | 2004-12-29 | Astrazeneca AB | 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| JP2009510160A (ja) * | 2005-10-03 | 2009-03-12 | アストラゼネカ・アクチエボラーグ | アルツハイマー病を予防および／または治療するための医薬の製造におけるピリミジン誘導体の使用 |
| ZA200804498B (en) | 2005-11-15 | 2009-07-29 | Array Biopharma Inc | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| NZ578744A (en) * | 2007-01-31 | 2012-02-24 | Vertex Pharma | 2-aminopyridine derivatives useful as kinase inhibitors |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| ES2524259T3 (es) * | 2008-03-24 | 2014-12-04 | Novartis Ag | Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida |
| WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| WO2010009155A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Fused heterocyclyc inhibitor compounds |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| CN104689316A (zh) | 2008-10-22 | 2015-06-10 | 弗·哈夫曼-拉罗切有限公司 | 轴突变性的调节 |
| US8178529B2 (en) | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
| CN102459159A (zh) | 2009-06-08 | 2012-05-16 | 吉利德科学股份有限公司 | 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物 |
| BRPI1010883A2 (pt) | 2009-06-08 | 2018-07-10 | Gilead Sciences Inc | compostos inibidores da anilina cicloalquilcarbamato benzamida hdac. |
| KR102414221B1 (ko) | 2020-08-04 | 2022-06-27 | 서울시립대학교 산학협력단 | 열전 소자 어셈블리, 이의 제조 방법, 및 이를 포함하는 열전 모듈 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE29032E (en) * | 1969-06-12 | 1976-11-09 | Riker Laboratories, Inc. | 3-Benzoylfluoro-methanesulfonanilides |
| FR2179493A1 (en) * | 1972-04-10 | 1973-11-23 | Roussel Uclaf | Amino benzhydrols - choleretics anticonvulsants sedatives and barbiturate potentiators |
| DE3042466A1 (de) * | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| TW225528B (cs) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9701453D0 (en) * | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
| GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
-
2001
- 2001-02-20 SE SE0100569A patent/SE0100569D0/xx unknown
-
2002
- 2002-02-18 SK SK1025-2003A patent/SK10252003A3/sk unknown
- 2002-02-18 HU HU0303254A patent/HUP0303254A2/hu unknown
- 2002-02-18 CA CA002434648A patent/CA2434648A1/en not_active Abandoned
- 2002-02-18 IL IL15678102A patent/IL156781A0/xx unknown
- 2002-02-18 KR KR10-2003-7010874A patent/KR20030084935A/ko not_active Application Discontinuation
- 2002-02-18 CN CNB028052471A patent/CN1294131C/zh not_active Expired - Fee Related
- 2002-02-18 WO PCT/SE2002/000271 patent/WO2002065979A2/en active IP Right Grant
- 2002-02-18 CZ CZ20032235A patent/CZ20032235A3/cs unknown
- 2002-02-18 EE EEP200300400A patent/EE200300400A/xx unknown
- 2002-02-18 JP JP2002565540A patent/JP4475869B2/ja not_active Expired - Lifetime
- 2002-02-18 RU RU2003121307/04A patent/RU2003121307A/ru not_active Application Discontinuation
- 2002-02-18 NZ NZ526783A patent/NZ526783A/en unknown
- 2002-02-18 US US10/468,604 patent/US7345050B2/en not_active Expired - Fee Related
- 2002-02-18 MX MXPA03007320A patent/MXPA03007320A/es unknown
- 2002-02-18 BR BR0206935-0A patent/BR0206935A/pt not_active IP Right Cessation
- 2002-02-18 EP EP02711620A patent/EP1373266A2/en not_active Withdrawn
- 2002-02-18 PL PL02363393A patent/PL363393A1/xx not_active Application Discontinuation
-
2003
- 2003-07-08 IS IS6868A patent/IS6868A/is unknown
- 2003-08-07 BG BG108070A patent/BG108070A/bg unknown
- 2003-08-08 ZA ZA200306171A patent/ZA200306171B/xx unknown
- 2003-08-19 NO NO20033679A patent/NO20033679L/no unknown
-
2005
- 2005-04-06 HK HK05102865A patent/HK1070071A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IS6868A (is) | 2003-07-08 |
| WO2002065979A3 (en) | 2003-02-20 |
| ZA200306171B (en) | 2004-11-08 |
| HUP0303254A2 (hu) | 2004-01-28 |
| CZ20032235A3 (cs) | 2004-01-14 |
| JP2004527486A (ja) | 2004-09-09 |
| US20040077642A1 (en) | 2004-04-22 |
| US7345050B2 (en) | 2008-03-18 |
| NO20033679D0 (no) | 2003-08-19 |
| CA2434648A1 (en) | 2002-08-29 |
| BG108070A (bg) | 2004-07-30 |
| NO20033679L (no) | 2003-08-19 |
| BR0206935A (pt) | 2004-06-29 |
| WO2002065979A2 (en) | 2002-08-29 |
| RU2003121307A (ru) | 2005-02-27 |
| PL363393A1 (en) | 2004-11-15 |
| CN1537112A (zh) | 2004-10-13 |
| SE0100569D0 (sv) | 2001-02-20 |
| KR20030084935A (ko) | 2003-11-01 |
| JP4475869B2 (ja) | 2010-06-09 |
| NZ526783A (en) | 2005-04-29 |
| EE200300400A (et) | 2003-12-15 |
| MXPA03007320A (es) | 2003-12-04 |
| HK1070071A1 (en) | 2005-06-10 |
| SK10252003A3 (sk) | 2004-02-03 |
| CN1294131C (zh) | 2007-01-10 |
| EP1373266A2 (en) | 2004-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL156781A0 (en) | (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes | |
| HK1109867A1 (en) | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | |
| IL144995A0 (en) | Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders | |
| AU2002357676A1 (en) | Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation | |
| PL374118A1 (en) | Interleukin-1 receptors in the treatment of diseases | |
| IL156865A0 (en) | D-amino acid oxidase and d-aspartate oxidase for use in cns disorders | |
| AU2003255993A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
| HUP0303344A3 (en) | Carbamate compounds for use in preventing and treating movement disorders | |
| PL372322A1 (en) | Low dose liquid entecavir formulations and use | |
| IL157593A0 (en) | Carbamate compounds for use in the treatment of pain | |
| IL160018A0 (en) | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | |
| AU2002362115A8 (en) | Composition and methods for treatment of neurological disorders | |
| GB0128674D0 (en) | Treatment of sleep disorders and the like | |
| IL163926A0 (en) | Crystal structure of phosphodiesterase 5 and use thereof | |
| HUP0402326A3 (en) | Pharmaceutical composition for prevention of addiction in pain management | |
| AU2001248971A1 (en) | Use of npy y1 receptor agonists in the treatment of pain conditions | |
| EP1371371A4 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SEXUAL DISORDERS | |
| EP1406720A4 (en) | BUFFERS FOR ELECTROPHORESIS AND USE THEREOF | |
| IL161388A0 (en) | Method of reducing type 2 diabetes in high risk patients | |
| GB0130248D0 (en) | Delivering content | |
| AU2002328173A1 (en) | Omoxin agonists and antagonists for use in the treatment of metabolic disorders | |
| AU2002339682A1 (en) | Emergen agonists and antagonists for use in the treatment of metabolic disorders | |
| IL161441A0 (en) | Pathway of rantes-mediated chemokine synthesis in astrocytes and method of use therefor | |
| AU2002321774A1 (en) | Agonists and antagonists of contabix for use in the treatment of metabolic disorders | |
| AU2002324296A1 (en) | Agonists and antagonists of energen for use in the treatment of metabolic disorders |